Edition:
India

Axovant Sciences Ltd (AXON.OQ)

AXON.OQ on NASDAQ Stock Exchange Global Select Market

4.99USD
17 Nov 2017
Change (% chg)

$-0.04 (-0.80%)
Prev Close
$5.03
Open
$5.08
Day's High
$5.20
Day's Low
$4.96
Volume
239,600
Avg. Vol
381,734
52-wk High
$27.93
52-wk Low
$4.60

Latest Key Developments (Source: Significant Developments)

Axovant announces second fiscal quarter results
Friday, 3 Nov 2017 

Nov 2 (Reuters) - Axovant Sciences Ltd :Axovant announces second fiscal quarter financial results and corporate updates.Q2 loss per share $0.64.Q2 earnings per share view $-0.55 -- Thomson Reuters I/B/E/S.Axovant Sciences Ltd - ‍Axovant held cash of $235.4 million at september 30, 2017​.  Full Article

Axovant sciences says exploring nelotanserin as treatment for Rem sleep behavior disorder
Monday, 13 Feb 2017 

Axovant Sciences Ltd : Axovant sciences announces preliminary results from interim analysis of phase 2 study testing investigational drug nelotanserin in Lewy body dementia patients . Axovant expects to initiate phase 3 program in second half of 2017 . Plans to expand study recruitment to further explore updrs findings and expects final results in mid-2017 . Axovant Sciences-in interim analysis, secondary endpoints did not demonstrate statistically significant differences for nelotanserin relative to placebo .Axovant Sciences-is exploring nelotanserin as a potential treatment for rem sleep behavior disorder (RBD) in patients with dementia with Lewy bodies.  Full Article

Axovant Sciences receives FDA fast-track designation for intepirdine
Monday, 26 Sep 2016 

Axovant Sciences Ltd :Axovant Sciences receives FDA fast-track designation for intepirdine as an investigational treatment for dementia with lewy bodies.  Full Article

Axovant Sciences posts Q1 loss per share of $0.38
Tuesday, 16 Aug 2016 

Axovant Sciences Ltd : Axovant sciences announces expansion of dementia pipeline and reports financial results for the first fiscal quarter ended June 30, 2016 . Q1 loss per share $0.38 . Q1 earnings per share view $-0.36 -- Thomson Reuters I/B/E/S . Axovant says Axovant and QAAM Pharmaceuticals (QAAM) have entered into an exclusive license agreement . Axovant says financial terms of transaction were not disclosed . Axovant plans to initiate clinical studies for RVT-103 shortly, with initial results expected in 2017 . Announces plan to develop RVT-103, a combination of Glycopyrrolate and Donepezil, as a potential treatment for patients with dementia .Axovant sciences ltd says axovant does not expect program to have a material effect on its use of cash in fiscal year ending March 31, 2017.  Full Article

Axovant Q4 loss per share $0.30
Monday, 6 Jun 2016 

Axovant Sciences : Q4 loss per share $0.30 .Q4 earnings per share view $-0.30 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Axovant announces second fiscal quarter results

* Axovant announces second fiscal quarter financial results and corporate updates